MX341482B - Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. - Google Patents

Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.

Info

Publication number
MX341482B
MX341482B MX2012009503A MX2012009503A MX341482B MX 341482 B MX341482 B MX 341482B MX 2012009503 A MX2012009503 A MX 2012009503A MX 2012009503 A MX2012009503 A MX 2012009503A MX 341482 B MX341482 B MX 341482B
Authority
MX
Mexico
Prior art keywords
treatment
allergy
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2012009503A
Other languages
English (en)
Other versions
MX2012009503A (es
Inventor
Koizumi Shinichi
Okumura Takako
Nonomura Kazuhiko
Kanazawa Kiyoshi
Original Assignee
Raqualia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc filed Critical Raqualia Pharma Inc
Publication of MX2012009503A publication Critical patent/MX2012009503A/es
Publication of MX341482B publication Critical patent/MX341482B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere a un compuesto con actividad antagónica al EP4 o a una sal farmacéuticamente aceptable de éste con actividad antagónica al receptor EP4, la cual es útil en el tratamiento de enfermedad inmune o alergia. Esta invención también se refiere a un compuesto de fórmula (I), (II), (III), (IV), (Va) o (Vb), o una sal farmacéuticamente aceptable de éste con actividades antagónicas al receptor EP4, el cual es útil en el tratamiento de enfermedad inmune o alergia. Esta invención también se refiere a una composición farmacéutica para el tratamiento de enfermedad inmune o alergia, la cual comprende una cantidad terapéuticamente efectiva de un compuesto de fórmula (I), (II), (III), (IV), (Va) o (Vb), o una sal farmacéuticamente aceptable de éste. Adicionalmente, esta invención se refiere a un método para el tratamiento de enfermedad inmune o alergia en un sujeto animal, incluyendo un sujeto mamífero, el cual comprende la administración al sujeto animal, incluyendo un sujeto mamífero, de un compuesto de fórmula (I), (II), (III), (IV), (Va) o (Vb), o una sal farmacéuticamente aceptable de éste. (ver fórmulas).
MX2012009503A 2010-02-22 2011-02-22 Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23. MX341482B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28250610P 2010-02-22 2010-02-22
PCT/JP2011/000994 WO2011102149A1 (en) 2010-02-22 2011-02-22 Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases

Publications (2)

Publication Number Publication Date
MX2012009503A MX2012009503A (es) 2012-09-12
MX341482B true MX341482B (es) 2016-08-22

Family

ID=44482754

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009503A MX341482B (es) 2010-02-22 2011-02-22 Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.

Country Status (12)

Country Link
US (1) US9457084B2 (es)
EP (1) EP2538978B1 (es)
JP (2) JP6152643B2 (es)
KR (1) KR101780666B1 (es)
CN (2) CN107693518A (es)
BR (1) BR112012020236A2 (es)
CA (2) CA2789665C (es)
ES (1) ES2600355T3 (es)
HK (1) HK1249401A1 (es)
MX (1) MX341482B (es)
RU (1) RU2571816C2 (es)
WO (1) WO2011102149A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
EA028921B1 (ru) 2013-12-17 2018-01-31 Эли Лилли Энд Компани Феноксиэтилы
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
WO2015134792A1 (en) 2014-03-06 2015-09-11 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
US12109218B2 (en) 2014-12-09 2024-10-08 Aratana Therapeutics, Inc. Compositions of grapiprant and methods for using the same
MX390051B (es) * 2015-10-16 2025-03-20 Eisai R&D Man Co Ltd Antagonistas de ep4.
US10342785B2 (en) * 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
JP7163293B2 (ja) 2017-01-23 2022-10-31 ジェネンテック， インコーポレイテッド インターロイキン－１活性の阻害剤としての化学化合物
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
US10973834B2 (en) 2018-04-16 2021-04-13 Arrys Therapeutics, Inc. EP4 inhibitors and use thereof
WO2019245590A1 (en) 2018-06-18 2019-12-26 Avista Pharma Solutions, Inc. Chemical compounds
WO2020014465A1 (en) 2018-07-11 2020-01-16 Arrys Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3104199A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonylurea compounds as inhibitors of interleukin-1 activity
PE20211811A1 (es) 2018-07-20 2021-09-14 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
EP3917932A4 (en) 2019-01-30 2022-09-28 Avista Pharma Solutions, Inc. CHEMICAL COMPOUNDS
CA3128346A1 (en) 2019-01-30 2020-08-06 Avista Pharma Solutions, Inc. Synthetic process and novel intermediates
CN115697317A (zh) * 2020-04-08 2023-02-03 株式会社AskAt Ep4受体拮抗剂用于治疗肝癌、黑色素瘤、淋巴瘤和白血病的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2001000224A (es) * 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
PL373246A1 (en) 2002-04-12 2005-08-22 Pfizer Inc. Use of ep4 receptor ligands in the treatment of il-6 involved diseases
CN100408570C (zh) * 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
RS20060143A (sr) * 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
CA2563356A1 (en) * 2004-04-20 2005-11-03 Pfizer Products Inc. Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
JP4054368B2 (ja) * 2004-05-04 2008-02-27 ファイザー株式会社 置換メチルアリール又はヘテロアリールアミド化合物
ES2344310T3 (es) 2005-03-11 2010-08-24 Raqualia Pharma Inc Formas cristalinas de un derivado de imidazol.
CA2660133C (en) * 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
EP1886987A1 (en) * 2006-08-11 2008-02-13 Givaudan S.A. Process for producing 2,2,3-trimethylcyclopent-3-enecarbaldehyde (campholytic aldehyde)

Also Published As

Publication number Publication date
KR20130040787A (ko) 2013-04-24
WO2011102149A1 (en) 2011-08-25
CA2789665A1 (en) 2011-08-25
BR112012020236A2 (pt) 2016-05-17
JP6152643B2 (ja) 2017-06-28
HK1249401A1 (zh) 2018-11-02
US20120316197A1 (en) 2012-12-13
ES2600355T3 (es) 2017-02-08
CA3009937A1 (en) 2011-08-25
JP2013520397A (ja) 2013-06-06
EP2538978A4 (en) 2013-10-16
CN102770159A (zh) 2012-11-07
US9457084B2 (en) 2016-10-04
CA3009937C (en) 2020-12-15
KR101780666B1 (ko) 2017-09-21
HK1178088A1 (zh) 2013-09-06
CA2789665C (en) 2020-06-16
CN107693518A (zh) 2018-02-16
EP2538978A1 (en) 2013-01-02
MX2012009503A (es) 2012-09-12
RU2012140450A (ru) 2014-03-27
JP2017095511A (ja) 2017-06-01
RU2571816C2 (ru) 2015-12-20
EP2538978B1 (en) 2016-09-07

Similar Documents

Publication Publication Date Title
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
HK1220386A1 (zh) Ep4受体拮抗剂在软骨疾病的治疗中的用途
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
MD20140059A2 (en) Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases
MX2016003456A (es) Compuestos aminopirimidina sustituidos y metodos de uso.
IN2012DN06720A (es)
MY186126A (en) Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
MX2014002395A (es) Inhibidores de rock suaves, novedosos.
PH12014500386A1 (en) Combination treatment for hepatitis c
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
EA201491007A1 (ru) Лекарственные составы
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.
EA201390653A1 (ru) Aa антагонисты как усилители когнитивной и моторной функций
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
UA117154C2 (uk) Антагоністи s1p3
MX2013006768A (es) Moduladores de receptor de glucagon.
IN2013DN02555A (es)

Legal Events

Date Code Title Description
FG Grant or registration